Background Metformin is an oral anti‐hyperglycemic agent that has been shown to reduce
total mortality compared to other anti‐hyperglycemic agents, in the treatment of type 2 …

Chronic obstructive pulmonary disease (COPD) is a major incurable global health burden
and is currently the 4th largest cause of death in the world. Importantly, much of the disease …

Obesity is associated with increased cardiovascular disease. Metabolic syndrome (MS)
identifies substantial additional cardiovascular risk beyond the individual risk factors, and is …

Ageing can be defined as the progressive failure of repair and maintenance systems with a
consequent accumulation of cellular damage in nucleic acids, proteins, and lipids. These …

This review article is intended to describe the strong relationship between oxidative stress
and vascular disease. Reactive oxygen species (ROS) play an important role in the …

Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse
outcomes after a cardiovascular event has occurred. This situation might be caused, at least …

Central obesity is a relevant risk factor for major cardiovascular events due to the
atherosclerotic involvement of coronary, cerebral and lower limb arterial vessels. A major …

Nonalcoholic fatty liver disease is associated with chronic oxidative stress. In our study, we
explored the antioxidant effect of antidiabetic metformin on chronic [high-fat diet (HFD) …

Heart failure is an important manifestation of diabetic heart disease. Before the development
of symptomatic heart failure, as much as 50% of patients with type 2 diabetes mellitus …

Long-term use of anti-diabetic agents has become commonplace as rates of obesity,
metabolic syndrome and diabetes continue to escalate. Metformin, a commonly used anti …